OMERS ADMINISTRATION Corp Raises Stake in DaVita Inc. $DVA

Key Points

• OMERS ADMINISTRATION Corp increased its stake in DaVita Inc. by 18.8%, holding 13,412 shares valued at approximately $2.05 million as of the end of the recent quarter.
• DaVita Inc. reported $2.95 EPS for the last quarter, exceeding analyst expectations, with revenues rising by 6.1% year-over-year to $3.38 billion.
• Analysts have mixed opinions on DaVita's stock, with price targets ranging from $148 to $164 and a consensus rating of "Hold".

OMERS ADMINISTRATION Corp boosted its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 18.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,412 shares of the company's stock after purchasing an additional 2,125 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in DaVita were worth $2,052,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in DVA. Invesco Ltd. raised its stake in shares of DaVita by 3.4% in the first quarter. Invesco Ltd. now owns 1,642,947 shares of the company's stock worth $251,322,000 after purchasing an additional 53,402 shares during the last quarter. Northern Trust Corp raised its stake in shares of DaVita by 20.2% in the first quarter. Northern Trust Corp now owns 890,632 shares of the company's stock worth $136,240,000 after purchasing an additional 149,858 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of DaVita by 14.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company's stock worth $69,697,000 after purchasing an additional 57,386 shares during the last quarter. Epoch Investment Partners Inc. raised its stake in shares of DaVita by 10.7% in the first quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company's stock worth $62,400,000 after purchasing an additional 39,485 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in shares of DaVita by 35.2% in the fourth quarter. Deutsche Bank AG now owns 392,422 shares of the company's stock worth $58,687,000 after purchasing an additional 102,230 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Price Performance

DVA traded up $0.30 during trading on Thursday, hitting $136.27. The company's stock had a trading volume of 420,743 shares, compared to its average volume of 852,989. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18. DaVita Inc. has a twelve month low of $126.07 and a twelve month high of $179.60. The business's fifty day simple moving average is $139.59 and its 200 day simple moving average is $142.20. The firm has a market capitalization of $9.74 billion, a price-to-earnings ratio of 13.37, a P/E/G ratio of 0.99 and a beta of 1.13.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating the consensus estimate of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The company had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same period last year, the company earned $2.00 earnings per share. DaVita's quarterly revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, equities research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on DVA shares. Barclays reduced their price objective on DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. Truist Financial set a $148.00 price target on DaVita in a research report on Friday, August 8th. Finally, Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Friday, August 22nd. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, DaVita currently has a consensus rating of "Hold" and an average price target of $164.00.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 2,351 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the sale, the insider directly owned 26,038 shares of the company's stock, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.50% of the company's stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.